Go UK Bio - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Go UK Bio


Pharmaceutical Technology Europe
Volume 24, Issue 1

Firstly, Happy New Year! Please help yourself to a slice of cake.


Rich Whitworth
Towards the end of last year, I attended the 8th bioProcessUK conference in Glasgow, Scotland, with the tagline "Advancing Next Generation Therapies." The meeting was held in the very fitting Glasgow Science Centre, a place where children young and old can be inspired by the science around them—the next generation of pharma industry employees perhaps? There was a clear agenda to the conference—how to ensure that advances made in research result in actual therapies.

In all areas of pharmaceutical development, one of the recurring challenges is scale-up, so of particular interest was a thought-provoking talk given by Roslin Cell's Aidan Courtney on scaling up cell manufacture from the point of view of translating research protocols into GMP processes. He noted, "the destination defines the journey," i.e., depending on the application of a particular cell therapy, the quantity of cells required for treatment becomes a crucial parameter. Courtney went on to provide numbers for a couple of example scale-up scenarios; ischemia therapy would probably require 108 cells per treatment, so estimating perhaps 10,000 treatments per year, the numbers start multiplying faster than the cells... He concluded that GMP translation and scale-up are challenges best addressed in tandem.

Bridging the gap between discovery into development and onto commercial scale manufacturing is something that our sister publication, BioPharm International, is addressing in collaboration with BIO SmartBrief: "Drug Development Basic Training". I encourage you to check out some of the weekly articles and podcasts at http://BioPharmInternational.com/biosmart/ and to sign up for BIO SmartBrief.

I leave you with the passionate words of this year's winner of the Peter Dunnill Award, Professor Mike Hoare from University College London, who concluded in his bioProcessUK presentation on ultra scale-down for enhanced bioprocess discovery: "Design for manufacture; design for lower cost."

Best wishes
Rich Whitworth

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here